In vitro metabolism of gefitinib in human liver microsomes

Xenobiotica

Volumn 34, Issue 11-12, 2004, Pages 983-1000

  McKillop, D ^a   McCormick, A D ^a   Miles, G S ^a   Phillips, P J ^a   Pickup, K J ^a   Bushby, N ^a   Hutchison, M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; M 387783; M 523595; M 537194; M 605207; M 605212; M 608236; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; DEFLUORINATION; DEMETHYLATION; DRUG EFFECT; DRUG METABOLISM; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; RING OPENING; TUMOR GROWTH;

CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; QUINAZOLINES;

EID: 11244347797     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/02772240400015222     Document Type: Article

References (28)

1. BARKER, A. J., GIBSON, K. H., GRUNDY, W., GODFREY, A. A., BARLOW, J. J., HEALY, M. P., WOODBURN, J. R., ASHTON, S. E., CURRY, B. J., SCARLETT, L., HENTHORN, L. and RICHARDS, L., 2001, Studies leading to the identification of ZD1839 (Iressa): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic and Medicinal Chemistry Letters, 11, 1911-1914.
2. CHEN, H., CHEN, W., GAN, L.-S. and MUTLIB, A. E., 2003, Metabolism of (S)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H) -quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics. Drug Metabolism and Disposition, 31, 122-132.
3. CIARDIELLO, F. and TORTORA, G., 2002, Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opinion on Investigational Drugs, 11, 755-768.
4. DENISSEN, J. F., GRABOWSKI, B. A., JOHNSON, M. K., BOYD, S. A., UCHIC, J. T., STEIN, H., CEPA, S. and HILL, P., 1994, The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans. Drug Metabolism and Disposition, 22, 880-888.
5. DI FIORE, P. P., PIERCE, J. H., KRAUS, M. H., SEGATTO, O., KING, C. R. and AARONSON, S. A., 1987, erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-182.
6. ENNIS, B. W., LlPPMAN, M. E. and DICKSON, R. B., 1991, The EGF receptor system as a target for antitumor therapy. Cancer Investigation, 9, 553-562.
7. FUKUOKA, M., YANO, S., GIACCONE, G., TAMURA, T., NAKAGAWA, K., DOUILLARD, J. Y., NISHIWAKI, Y., VANSTEENKISTE, J., KUDOH, S., RISCHIN, D., EEK, R., HORAI, T., NODA, K., TAKATA, I., SMIT, E., AVERBUCH, S., MACLEOD, A., FEYEREISLOVA, A., DONG, R. P. and BASELGA, J., 2003, Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 21, 2237-2246.
8. GIBSON, K. H., GRUNDY, W., GODFREY, A. A., WOODBURN, J. R., ASHTON, S. E., CURRY, B. J., SCARLETT, L., BARKER, A. J. and BROWN, D. S., 1997, Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines. Bioorganic and Medicinal Chemistry Letters, 7, 2723-2728.
9. HERBST, R. S., MADDOX, A. M., ROTHENBERG, M. L., SMALL, E. J., RUBIN, E. H., BASELGA, J., ROJO, F., HONG, W. K., SWAISLAND, H., AVERBUCH, S. D., OCHS, J. and LoRusso, P. M., 2002, Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of Clinical Oncology, 20, 3815-3825.
10. HUSKEY, S.-E. W., DEAN, B. J., Doss, G. A., WANG, Z., HOP, C. E. C. A., ANARI, R., FINKE, P. E., ROBICHAUD, A. J., ZHANG, M., WANG, B., STRAUSS, J. R., CUNNINGHAM, P. K., FEENEY. W. P., FRANKLIN, R. B., BAILLIE, T. A. and CHIU, S.-H. L., 2004, The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metabolism and Disposition, 32, 246-258.
11. KRIS, M. G., NATALE, R. B., HERBST, R. S., LYNCH, Jr, T. J., PRAGER, D., BELANI, C. P., SCHILLER, J. H., KELLY, K., SPIRIDONIDIS, H., SANDLER, A., ALBAIN, K. S., CELLA, D., WOLF, M. K., AVERBUCH, S. D., OCHS, J. J. and KAY, A. C., 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. Journal of the American Medical Association, 290, 2149-2158.
12. MAYERSOHN, M. and GUENTERT, T. W., 1995, Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clinical Pharmacokinetics, 29, 292-332.
13. MCKILLOP, D., HUTCHISON, M., PARTRIDGE, E. A., BUSHBY, N., COOPER, C. M. F., CLARKSON-JONES, J. A., HERRON, W. and SWAISLAND, H. C., 2004a, Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica, 34, 917-934.
14. MCKILLOP, D., PARTRIDGE, E. A., HUTCHISON, M., PARRY, A. C., BARDSLEY, J., WOODMAN, H. M. and SWAISILAND, H. C., 2004b, Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica, 34, 901-915.
15. MCKILLOP, D., WILD, M. J., BUTTERS, C. J. and SIMCOCK, C., 1998, Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica, 28, 845-853.
16. MUTCH, P. J., DEAR, G. J. and ISMAIL, I. M., 2001, Formation of a defluorinated metabolite of a quinoxaline antiviral drug catalysed by human cytochrome P450 1A2. Journal of Pharmacy and Pharmacology, 53, 403-408.
17. PARK, Y. H., HUDSON, J. E., BARKER, R. C., YORK, B. M. and BRAZZELL, R. K., 1991, Metabolism of the aldose reductase inhibitor ALO1567 in man. British Journal of Clinical Pharmacology, 32, 221-227.
18. RANSON, M., HAMMOND, L. A., FERRY, D., KRIS, M., TULLO, A., MURRAY, P. I., MILLER, V., AVERBUCH, S., OCHS, J., MORRIS, C., FEYEREISLOVA, A., SWAISLAND, H. and ROWINSKY, E. K., 2002, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of Clinical Oncology, 20, 2240-2250.
19. SAINSBURY, J. R., MALCOLM, A. J., APPLETON, D. R., FARNDON, J. R. and HARRIS, A. L., 1985, Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. Journal of Clinical Pathology, 38, 1225-1228.
20. SCARFE, G. B., TUGNAIT, M., WILSON, I. D. and NICHOLSON, J. K., 1999, Studies on the metabolism of 4-fluoroaniline and 4-fluoroacetanilide in rat: formation of 4-acetamidophenol (paracetamol) and its metabolites via defluorination and N-acetylation. Xenobiotica, 29, 205-216.
21. SIKOTNAK, F. M., ZAKOWSKI, M. F., MILLER, V. A., SCHER, H. I. and KRIS, M. G., 2000, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clinical Cancer Research, 6, 4885-4892.
22. SLAMON, D. J., CLARK, G. M., WONG, S. G., LEVIN, W. J., ULLRICH, A. and MCGUIRE, W. L., 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
23. 14C] linezolid to healthy human subjects. Drug Metabolism and Disposition, 29, 1136-1145.
24. SWAISLAND, H. C., RANSON, M., SMITH, R. P., LEADBETTER, J., LAIGHT, A., MCKILLOP, D. and WILD, M. J., 2004, Pharmacokinetic drug interactions with gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Pharmacokinetics (in press).
25. TOCCO, D. J., DUNCAN, A. E. W., DELUNA, F. A., SMITH, J. L., WALKER, R. W. and VANDENHEUVEL, W. J. A., 1980, Timolol metabolism in man and laboratory animals. Drug Metabolism and Disposition, 8, 236-240.
26. WAKELING, A. E., BARKER, A. J., DAVIES, D. H., BROWN, D. S., GREEN, L. R., CARTLIDGE, S. A. and WOODBURN, J. R., 1997, New targets for therapeutic attack. Endocrine-related Cancer, 4, 351-355.
27. WAKELING, A. E., GUY, S. P., WOODBURN, J. R., ASHTON, S. E., CURRY, B. J., BARKER, A. J. and GlBSON, K. H., 2002, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research, 62, 5749-5754.
28. WOODBURN, J. R., 1999, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology and Therapeutics, 82, 241-250.